Acquired von Willebrand disease

Mayo Clinic Proceedings

Volumn 77, Issue 2, 2002, Pages 181-187

  Kumar, Shaji ^a   Pruthi, Rajiv K ^a   Nichols, William L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; IMMUNOGLOBULIN; KOATE DVI; RISTOCETIN; VON WILLEBRAND FACTOR;

ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; CONGENITAL DISORDER; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFICACY; FAMILY HISTORY; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; SKIN BLOOD VESSEL DISORDER; VON WILLEBRAND DISEASE;

EID: 0036163386     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.2.181     Document Type: Article

References (101)

1. Epidemiological investigation of the prevalence of von Willebrand's disease
2. Acquired von Willebrand's syndrome in systemic lupus erythematosus
3. Acquired von Willebrand disease: Concise review of occurrence, diagnosis, pathogenesis, and treatment
4. Four cases of acquired von Willebrand's syndrome
5. Antibody-induced von Willebrand's disease: A newly defined inhibitor syndrome
6. Acquired von Willebrand syndrome: Data from an international registry
7. Estimation of prevalence and natural history of acquired von Willebrand disease
8. The factor VIII complex: Structure and function
9. Acquired von Willebrand's syndrome and thrombopathy in a patient with chronic lymphocytic leukaemia
10. Acquired type II von Willebrand's disease: Demonstration of a complexed inhibitor of the von Willebrand factor-platelet interaction and response to treatment
11. Acquired von Willebrand's disease in chronic lymphatic leukemia
12. Acquired Von Willebrand's syndrome associated with hairy cell leukaemia
13. Acquired von Willebrand's disease: Evidence for a quantitative and qualitative factor VIII disorder
14. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells
15. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen
16. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches
17. Acquired von Willebrand's disease
18. Acquired von Willebrand's syndrome in the course of Waldenstrom's disease
19. Acquired von Willebrand's disease: Demonstration of a circulating inhibitor to the factor VIII complex in four cases
20. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor
21. Acquired von Willebrand disease associated with multiple myeloma: Characterization of an inhibitor to von Willebrand factor
22. Acquired von Willebrand's disease caused by a chronic granulocytic leukaemia
23. Acquired type 2A von Willebrand disease in chronic myelocytic leukemia
24. Acquired von Willebrand disease and storage pool disease in chronic myelocytic leukemia
25. Acquired von Willebrand's disease in association with essential thrombocythemia: Regression following treatment
26. Essential thrombocythemia with acquired von Willebrand's disease
27. Acquired von Willebrand disease in patients with polycythemia rubra vera
28. Acquired von Willebrand syndrome due to an inhibitor specific for von Willebrand factor antigens
29. Acquired von Willebrand disease in a patient with Wilms tumor
30. Acquired Von Willebrand disease in children with a Wilms' tumor
31. Acquired von Willebrand disease in Wilms' tumor patients
32. Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma
33. Acquired von Willebrand disease: Correction of hemostatic defect by high-dose intravenous immunoglobulins
34. Acquired von Willebrand disease in malignant peripheral neuroectodermal tumor (PNET)
35. Clinical significance of inhibitors in acquired von Willebrand syndrome
36. Acquired von Willebrand's syndrome in association with a lupus-like anticoagulant corrected by intravenous immunoglobulin
37. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus
38. Development of acquired von Willebrand's disease after mixed connective tissue disease
39. Acquired von Willebrand's syndrome during collagen disorder (author's transl)
40. Acquired von Willebrand syndrome with autoimmune hemolytic anemia
41. Acquired von Willebrand syndrome - Report of 10 cases and review of the literature
42. Acquired von Willebrand disease in twins with autoimmune hypothyroidism: Response to desmopressin and L-thyroxine therapy
43. Acquired von Willebrand syndrome with inhibitors both to factor VIII clotting activity and ristocetin-induced platelet aggregation
44. Characterization of two cases of acquired transitory von Willebrand syndrome with ciprofloxacin: Evidence for heightened proteolysis of von Willebrand factor
45. Induction of von Willebrand disease type I by valproic acid
46. Hydroxyethyl starch induced acquired von Willebrand's disease
47. The effect of 6% hydroxyethyl starch and desmopressin infusion on von Willebrand factor: Ristocetin cofactor activity
48. Acquired von Willebrand factor deficiency during high-dose infusion of recombinant factor VIII
49. Acquired von Willebrand's disease, IgE polyclonal gammopathy and griseofulvin therapy
50. Embryonal adenoma of the kidney associated with polycythemia and von Willebrand disease
51. Willebrand syndrome acquired during an amylosis of primitive appearance
52. Idiopathic immune-mediated acquired von Willebrand's disease in a patient with angiodysplasia: Demonstration of an unusual inhibitor causing a functional defect and rapid clearance of von Willebrand factor
53. Acquired von Willebrand's disease, platelet-release defect and angiodysplasia
54. Abnormality of von Willebrand factor in patients with hemoglobin E-beta (0) thalassemia
55. Acquired von Willebrand's syndrome and Ehlers-Danlos syndrome presenting with gastro-intestinal bleeding
56. Acquired von Willebrand's disease due to excessive fibrinolysis
57. Acquired von Willebrand disease after Epstein-Barr virus infection
58. Acquired von Willebrand's disease following bone marrow transplantation
59. Acquired von Willebrand's syndrome associated with hydatid disease of the spleen - Disappearance after splenectomy
60. Production site of bleeding factor (acquired morbus von Willebrand)
61. Acquired von Willebrand disease in patients with high platelet counts
62. The bleeding diathesis in human glycogen storage disease type I: In vitro identification of a naturally occurring inhibitor of ristocetin-induced platelet aggregation
63. DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times
64. Plasma and platelet von Willebrand factor defects in uremia
65. Von Willebrand syndromes and mitral-valve prolapse: Linked mesenchymal dysplasias
66. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects
67. Changes in von Willebrand factor during cardiac surgery: Effect of desmopressin acetate
68. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies
69. Acquired type I von Willebrand's disease with essential thrombocytosis
70. Acquired von Willebrand's disease in the myeloproliferative syndrome
71. Multimeric composition of plasma von Willebrand factor in chronic myeloproliferative disorders
72. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor
73. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: An assay for von Willebrand factor binding by antibody
74. Puerperal acquired factor VIII inhibitor causing a von Willebrand-like syndrome in a patient with anti-DNA antibodies
75. Acquired von Willebrand's syndrome due to an inhibitor of IgG specific for von Willebrand's factor in polycythemia rubra vera
76. Acquired von Willebrand's disease caused by a monoclonal antibody
77. Acquired von Willebrand's syndrome with IgM inhibitor against von Willebrand's factor
78. Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism
79. Qualitative and quantitative abnormalities of von Willebrand antigen in patients with diabetes mellitus
80. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation
81. Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction
82. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells
83. A hemorrhagic syndrome in Waldenstrom's macroglobulinemia secondary to immuno-adsorption of factor VIII: Recovery after splenectomy
84. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease
85. Absence of a bleeding tendency in severe acquired von Willebrand's disease: The role of platelet von Willebrand factor in maintaining normal hemostasis
86. The effect of ABO blood group on the diagnosis of von Willebrand disease
87. Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor
88. The von Willebrand factor propolypeptide, von Willebrand antigen II (vWAgII), distinguishes acquired von Willebrand syndrome (AvWS) due to decreased synthesis of von Willebrand factor (vWF) from AvWS due to increased clearance of vWF
89. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome
90. The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome
91. Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor
92. Treatment of von Willebrand's disease
93. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years
94. DDAVP: A useful alternative to blood components in moderate hemophilia A and von Willebrand disease
95. High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease
96. Subunit composition of plasma von Willebrand factor (vWF) in two uremic patients with acquired vWF abnormalities
97. Acquired type 2a von Willebrand's disease: Response to immunoglobulin infusion
98. Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate
99. Immunoadsorption for coagulation factor inhibitors
100. Acquired von Willebrand's syndrome during autoimmune disorder
101. Acquired von Willebrand's disease and hypothyroidism: Report of a case presenting with menorrhagia